

**HepaLife Technologies Inc.:** Based in Boston, Massachusetts, HepaLife Technologies Inc.™, is developing its cell-based bioartificial liver system, HepaMate™, as a potentially lifesaving treatment for liver failure patients. The patented technology has previously been tested in clinical Phase I and pivotal Phase II/III studies involving more than 200 patients, making it the most clinically studied bioartificial liver. Over 50 scientific papers and book chapters have been published on the technology. HepaLife expects a new pivotal Phase III clinical trial to be successful in obtaining market approval for its HepaMate™ bioartificial liver system.

### **HepaMate™ Bioartificial Liver**

As an extracorporeal cell-based bioartificial liver system, HepaMate™ is designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. A patented liver cell cryopreservation process provides for safe and easy storing and distribution, a significant logistic and commercial advantage.

### **PICM-19 Stem Cell Line**

The company continues to evaluate the further optimization of the proprietary PICM-19 pig embryonic liver stem cell line for potential use in a future generation of the HepaMate™ bioartificial liver system. The PICM-19 is the world's only cell line of its kind with full expansion and growth capacity, maintaining its hepatic function in repeated passage. In 2008, due to its liver-like hepatic performance, the PICM-19 liver stem cell line was chosen to be part of a scientific experiment onboard the NASA Space Shuttle "Endeavour" Mission STS 126 to investigate the differentiation and function of stem cells in space and on the ability of the human liver to regenerate during space flight and under microgravity.